Anxiety and depression are common in patients with cancer and in palliative care settings. These symptoms can be reactive to the illness or can be related to the direct physiologic effects of the disease or to drug therapies. Effective treatment of these symptoms includes both psychopharmacologic and psychotherapeutic approaches. The newer antidepressants, anxiolytics, and hypnotics are better tolerated and can be continued safely if necessary, or they can be reduced and discontinued as symptoms improve. (Cancer J 2006;12:388-397) 
The diagnosis of cancer induces stresses that are caused by the patient' s perceptions of the disease, its manifestations, and the stigma commonly attached to this disease. Most individuals fear a painful death, becoming disabled and dependent, having altered appearance and changed body function, and losing the company of those close to them. The variability of psychological distress is related to medical factors (e.g., site and stage of illness, treatments offered, course of the cancer, and presence of pain); psychological factors (e.g., prior adjustment, history of losses, coping ability, emotional maturity, the disruption of life goals, and the ability to modify plans); cultural, spiritual, and social factors (e.g., availability of emotional support from family, friends, and coworkers); and financial stability. 1 The presence of intolera-ble or prolonged distress that compromises the usual function of the patient requires evaluation, diagnosis, and management.
N N O O R R M M A A L L R R E E S S P P O O N N S S E E S S T T O O T T H H E E S S T T R R E E S S S S O O F F C C A A N N C C E E R R
Individuals who receive a diagnosis of cancer or who learn that relapse has occurred or that treatment has failed often show a characteristic emotional response: a period of initial shock and disbelief, followed by a period of turmoil with mixed symptoms of anxiety and depression, irritability, and disruption of appetite and sleep. The ability to concentrate and carry out usual daily activities is impaired, and thoughts about the diagnosis and fears about the future may intrude. 2 These symptoms usually resolve over days to weeks with support from family, friends, and a physician who outlines a treatment plan that offers hope. Prescribing hypnotics for insomnia and anxiolytics to reduce anxiety can help the patient through this crisis period.
Some patients continue to have high levels of depression and anxiety that persist for weeks or months, is not adaptive, often impairs social or occupational functioning, frequently requires psychiatric treatment, and are classified as adjustment disorders. 3 Short-term supportive psychotherapy offers emotional support, provides information to help the patient adapt to the crisis, emphasizes past strengths, and supports previously successful ways of coping. Anxiolytic or antidepressant drugs are prescribed as indicated, and as symptoms improve, medication can be reduced and discontinued.
P P R R E E V V A A L L E E N N C C E E O O F F P P S S Y Y C C H H I I A A T T R R I I C C D D I I S S O O R R D D E E R R S S I I N N P P A A T T I I E E N N T T S S W W I I T T H H C C A A N N C C E E R R
One of the first efforts in the field of psychooncology was to obtain objective data on the type and frequency of psychological problems in cancer patients. The Psychosocial Collaborative Oncology Group (PSYCOG) determined the psychiatric disorders in 215 randomly selected hospitalized and ambulatory adult cancer patients in three cancer centers. 4 Although slightly more than half (53%) of the patients evaluated were adjusting normally to stress, the remainder (47%) had clinically apparent psychiatric disorders. Of the 47% with psychiatric disorders, more than two thirds (68%) had reactive or situational anxiety and depression (adjustment disorders with depressed or anxious mood), 13% had a major depression, 8% had an organic mental disorder, 7% had a personality disorder, and 4% had a preexisting anxiety disorder. The authors concluded that nearly 90% of the psychiatric disorders observed were reactions to, or manifestations of, disease or treatment.
Thirty-nine percent of those who received a psychiatric diagnosis were experiencing significant pain, whereas only 19% of patients who did not receive a psychiatric diagnosis had significant pain. The psychiatric diagnosis of the patients with pain was predominately adjustment disorder (69%); however, 15% of patients with significant pain had symptoms of major depression. In a study of cancer pain syndromes, unmanaged pain emerged as a causal factor in patient' s reports of increased anxiety. 5 Both data and clinical observation suggest that the psychiatric symptoms of patients who are in pain (e.g., acute anxiety, depression with despair, agitation, irritability, uncooperative behavior, anger, and inability to sleep) must initially be considered a consequence of uncontrolled pain. These symptoms are not labeled as a psychiatric disorder unless they persist after pain is adequately controlled. Clinicians should manage pain 6 and then reassess the patient' s mental state after pain is controlled to determine whether the patient has a psychiatric disorder.
I I M M P P A A C C T T O O F F D D E E P P R R E E S S S S I I O O N N A A N N D D A A N N X X I I E E T T Y Y O O N N T T H H E E M M A A N N A A G G E E M M E E N N T T O O F F P P A A T T I I E E N N T T S S W W I I T T H H C C A A N N C C E E R R
A meta-analysis of the effects of depression and anxiety on compliance with medical treatment suggests that depressed patients are three times more likely to be noncompliant than nondepressed patients. 7 Additionally, depression may impair patients' capacity to understand and process information about their prognosis.
P P R R E E V V A A L L E E N N C C E E O O F F D D E E P P R R E E S S S S I I O O N N I I N N P P A A T T I I E E N N T T S S W W I I T T H H C C A A N N C C E E R R
The prevalence of major depression in cancer patients ranges from zero to 38%, and the prevalence of depression spectrum syndromes ranges from zero to 58%. 8 Most of this variance can be attributed to the lack of standardization of methodology and diagnostic criteria. For example, in a study of 152 oncology patients, Kathol and colleagues 9 found a 13% differ-ence (25% vs 38%) in the prevalence of depression, depending on the diagnostic system used. The clinical rule of thumb is that 25% of cancer patients are likely to be depressed enough at some point in the course of disease to warrant evaluation and treatment.
Greater physical disability is associated with a higher prevalence of depression. The reported prevalence of depression in patients with advanced cancer has been found to be as high as 26%. 8, 10 
D D I I A A G G N N O O S S I I S S O O F F D D E E P P R R E E S S S S I I O O N N I I N N P P A A T T I I E E N N T T S S W W I I T T H H C C A A N N C C E E R R
Somatic symptoms, such as anorexia, fatigue, insomnia, and weight loss, are of less value as diagnostic criteria for depression in cancer patients, because they are common to both cancer and depression. In cancer patients, the diagnosis of depression must depend on psychological (i.e., dysphoric mood, feelings of helplessness and hopelessness, loss of self-esteem, feelings of worthlessness or guilt, anhedonia, and thoughts of death or suicide), not somatic symptoms.
A depressive syndrome caused by the direct physiological effects of cancer is called "mood disorder due to cancer." Tumor involvement of the central nervous system, metabolic disturbances (e.g., hypothyroidism, hyperparathyroidism, adrenal insufficiency, folate and B 12 deficiencies), and the presumed organic processes associated with carcinoma of the pancreas may be contributing factors to a mood disorder.
The diagnosis of a "substance-induced mood disorder" is appropriate when depression is related to drug therapies (Table 1) , including anticancer drugs ( Table  2 ). There are several reports of exogenously administered cytokines, such as interferon-alpha and interleukin-2, causing depression. These cytokine therapies have been shown to be associated with significant depressive symptoms in 30% to 50% of patients. 11 The evaluation of every depressed cancer patient includes a consideration of medical, endocrinologic, and neurologic problems. If the depressive disorder is believed to be caused by a medical condition or a drug, the clinician should first attempt to treat the disorder or change the drug. When the primary cause of the depression cannot be corrected (e.g., the chemotherapeutic agent must be continued), or the clinician believes that the depression will not be relieved by addressing the medical condition alone, an antidepressant is started concurrently.
S S U U I I C C I I D D E E
Suicidal ideation requires careful assessment to determine whether the patient has a depressive illness or is expressing a wish to have ultimate control over intol-erable symptoms. Although few cancer patients commit suicide, they may be at somewhat greater risk than the general population. 12 Table 3 reviews the risk factors for suicide in cancer patients.
Factors such as poor prognosis, delirium, uncontrolled pain, depression, and hopelessness often occur in a patient with advanced disease, increasing the risk of suicide. Hopelessness is an even stronger predictive factor than depression itself. 13 Studies exploring the desire for hastened death have found that 1% to 17% of terminally ill cancer patients wish to have their lives end naturally or by suicide or euthanasia. Figures range depending on the assessment tools used and populations studied. 14 The management of the suicidal cancer patient includes maintaining a supportive therapeutic relationship; conveying the attitude that much can be done to improve the quality, if not the quantity, of life even if the prognosis is poor; and actively eliciting and treating specific symptoms (e.g., pain, nausea, insomnia, anxiety, fatigue, and depression). The most useful psychotherapeutic modalities are based on a crisis intervention model using cognitive techniques and supportive methods, sometimes involving family and friends.
When the need to hospitalize a suicidal patient is considered, evaluation of the risk factors (Table 3) , including the presence of a plan and its lethality, and associated intent ensues. If the suicidal patient does not have any physiologic factors contributing to his or her psychiatric presentation, admitting the patient to a psychiatric unit may be indicated. However, during the palliative phase, when patients are too ill to be psychiatrically hospitalized, they may be admitted to oncology wards, where a 24-hour companion can be provided. Companions can provide constant observation, monitor the suicidal risk, and reassure the patient. Need for observation is evaluated daily; companions are discontinued when the patient is no longer suicidal and is judged to be in control and able to act rationally. Similarly, companions or nurses can be provided in hospice settings or in the home to ensure patient safety.
T T R R E E A A T T M M E E N N T T O O F F D D E E P P R R E E S S S S I I O O N N
Before planning an intervention, the patient should be evaluated for a history of depressive episodes and substance abuse; family psychiatric history, including 
Drugs Associated with

Anticancer Drugs Associated TABLE 22 with Depression
Drug
Corticosteroids Vinblastine Vincristine Vinorelbine Interferon Procarbazine Asparaginase Tamoxifen Cyproterone depression and suicide; concurrent life stresses; losses secondary to cancer (e.g., financial, social, and occupational), and availability of social support. An assessment of the patient' s own personal experience with cancer deaths, of the meaning of illness, and of the patient' s understanding of the medical situation (including prognosis) is essential. Depressed patients with cancer are usually treated with a combination of supportive psychotherapy, antidepressants, and psychostimulants.
P Ps sy yc ch ho ol lo og gi ic ca al l T Tr re ea at tm me en nt t
Evidence from meta-analyses has shown that psychological treatments effectively treat anxiety and depression in cancer patients. [15] [16] [17] The goals of psychotherapy are to reduce emotional distress and to improve morale, coping ability, self-esteem, sense of control, and resolution of problems. Cancer patients are often referred for, or request, psychiatric consultation at times of crisis in illness-at the time of initial diagnosis or recurrence, at the beginning of new treatments, when standard or experimental treatments fail, or when patients perceive themselves as dying.
Psychotherapy may be delivered to patients individually, in a group setting, or in sessions with their partner and/or family. Various models of psychotherapy may be used in the psychooncology population (e.g., psychoeducational, supportive, grief, existen-tial, cognitive behavioral, interpersonal, psychodynamic, life narrative, dignity conserving, and meaning centered). 18 As patients enter the terminal phase of their illness, the focus shifts to existential, spiritual, and relationship themes. At this time, implementing techniques from dignity-conserving and meaning-centered psychotherapies, both developed from an existential model, is useful. 19 D Dr ru ug g T Th he er ra ap pi ie es s Antidepressants Although there are many reports of the efficacy of antidepressants in depressed patients with cancer, there are few randomized, placebocontrolled trials. This observation reflects the difficulty in conducting controlled studies of drugs in medically ill cancer patients. Nonetheless, there is much clinical experience with antidepressant drugs in this population. A specific antidepressant is often chosen based on its side effect profile. The antidepressant agents that are better tolerated in patients with comorbid depression and medical conditions are the newer agents, including selective serotonin reuptake inhibitors (SSRIs) and the novel or mixedaction antidepressants. Tricyclic antidepressants (TCAs); psychostimulants; mood stabilizers, such as lithium carbonate; and monoamine oxidase inhibitors (MAOIs) are used for selected patients (Table 4 ).
SSRIs
The SSRIs (fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, and escitalopram) and novel antidepressants are considered the first-line treatment because they are better tolerated, have fewer sedative and autonomic effects, and have a safe cardiac profile. The most common side effects are nausea, headache, somnolence or insomnia, sexual dysfunction, and a brief period of increased anxiety. These drugs can cause appetite suppression that usually lasts a period of several weeks, but the anorectic properties of these drugs are not a limiting factor in this population. A risk of developing the syndrome of inappropriate secretion of antidiuretic hormone also exists with SSRIs. All SSRIs are equally efficacious, with depressive symptoms improving after 2 to 4 weeks of a therapeutic dose (see Table 4 for recommended dosing). Although the SSRIs share a similar side effect profile, there are some clinically relevant differences. Fluoxetine, for example, has the longest half-life (5 weeks), resulting in little if any risk of SSRI discontinuation syndrome with abrupt withdrawal. Because of the relative short half-life (24 hours) of the other SSRIs, patients are at risk for developing significant psychiatric, neurologic, gastrointestinal or flulike symptoms after abrupt withdrawal. Paroxetine leads to the most anti- cholinergic side effects of the SSRIs and causes the most weight gain. Fluvoxamine and paroxetine are more sedating, whereas fluoxetine is the most stimulating. The former are often chosen for highly anxious patients, whereas the latter is used for patients with anergic depression. Sertraline, citalopram, and escitalopram have fewer drug interactions, whereas fluvoxamine has the most, and this feature often limits its use. Musselman and colleagues 20 have demonstrated that paroxetine, started at the time interferon-alpha is started, reduces the incidence of depression. Additionally, citalopram, sertraline, fluoxetine, and mirtazapine have been shown to treat interferon-alpha-induced depression in clinical trials with patients with hepatitis C or cancer. 21, 22 N No ov ve el l a an nd d M Mi ix xe ed d--A Ac ct ti io on n A An nt ti id de ep pr re es ss sa an nt ts s
The novel and mixed-action antidepressants (venlafaxine, duloxetine, bupropion, trazodone, and mirtazapine) differ from the SSRIs in their mechanism of action, resulting in their different side effect profiles. Venlafaxine and duloxetine are serotonin/norepinephrine uptake inhibitors, with venlafaxine inhibiting serotonin reuptake at lower doses, thereby sharing some of the side effects of the SSRIs while in- hibiting norepinephrine reuptake at higher doses. At higher doses, usually greater than 225 mg daily, venlafaxine may contribute to hypertension. Both duloxetine and venlafaxine have been shown to improve neuropathic pain and peripheral neuropathy in cancer patients. Bupropion is primarily a noradrenergic agent that increases dopamine reuptake at higher doses. Its stimulating effects may be beneficial to the depressed cancer patient with fatigue. Bupropion has fewer gastrointestinal side effects than the SSRIs and tends to cause constipation more frequently than nausea, vomiting, or diarrhea. It increases the rise for seizures at higher doses and should be avoided or used with caution in patients with seizure disorders or organic brain pathology. Furthermore, it may assist in smoking cessation and has minimal effect on weight or sexual functioning. Although rare, it may contribute to confusion or psychotic symptoms in a delirious patient because of its effect on dopamine.
Venlafaxine, trazodone, mirtazapine, and SSRIs are useful in managing hot flashes. 23, 24 Trazodone may be used for its sedating properties and in low doses (50-100 mg at bedtime) is helpful in the treatment of the depressed cancer patient with insomnia. Trazodone has been associated with priapism and therefore should be used with caution in men. Mirtazapine is a noradrenergic and specific serotonergic antidepressant. It has low affinity for muscarinic, cholinergic, and dopaminergic receptors, but a high affinity for H 1 histaminic receptors. It antagonizes 5HT 2 and 5HT 3 receptors, resulting in increased serotonin release through 5HT 1 . It is through these mechanisms that the common features of sedation, anxiolysis, appetite stimulation, and antiemesis occur. Because it can cause weight gain, it may be advantageous in the palliative care setting for anorectic-cachectic cancer patients, but it is not a good choice for those who are gaining unwanted weight from steroids or chemotherapy.
T Tr ri ic cy yc cl li ic c A An nt ti id de ep pr re es ss sa an nt ts s
The TCAs antagonize muscarinic, cholinergic, H 1histaminic, and alpha 1 -adrenergic receptors, contributing to side effects of confusion, dry mouth, constipation, urinary retention, sedation, weight gain, and orthostatic hypotension. TCAs are still used in the oncology setting, especially when comorbid neuropathic pain is present.
P Ps sy yc ch ho os st ti im mu ul la an nt ts s a an nd d W Wa ak ke ef fu ul ln ne es ss s--P Pr ro om mo ot ti in ng g A Ag ge en nt ts s
In cancer patients, the psychostimulants (e.g., dextroamphetamine and methylphenidate) and the newer wakefulness-promoting agent modafinil promote a sense of well-being, decrease fatigue, improve concentration and attention, and stimulate appetite. An advantage of these drugs is their rapid effectiveness, and thus they are often preferred over antidepressants in the depressed patient with advanced cancer. Psychostimulants can potentiate the analgesic effects of opioid analgesics and are commonly used to counteract opioid-induced sedation. Occasionally, they can produce nightmares, agitation, insomnia, and even psychosis and lower the seizure threshold. At higher doses, they can cause tachycardia or hypertension. These same side effects occur less frequently with modafinil. Patients can be maintained on psychostimulants for long periods (e.g., > 1 year), and if tolerance develops, dose adjustments can be made.
A An nt ti ip ps sy yc ch ho ot ti ic cs s
Antipsychotics are started with antidepressants when patients are experiencing depression with psychotic features and may be used in patients with preexisting bipolar disorder or anxiety as a symptom of depression. Unlike the benzodiazepines, antipsychotics do not cause respiratory depression or confusion and are therefore useful in anxious cancer patients who often have altered mental states. Highpotency typical antipsychotics (e.g., haloperidol) or atypical antipsychotic medications (e.g., olanzapine and risperidone) are usually preferred because of their low anticholinergic potential, which reduces the risk of delirium and other anticholinergic side effects. These antipsychotics are less sedating and lower the seizure threshold less than low-potency antipsychotics (e.g., chlorpromazine) and are preferable when the risk of seizures is a concern. For patients who are unable to take oral medication, the typical antipsychotics, haloperidol and chlorpromazine, are available in intravenous form. Olanzapine is available in a disintegrating wafer, and risperidone has a similar formulation. Atypical antipsychotic medications that are used less frequently in the oncology or palliative care settings are quetiapine, ziprasidone, and aripiprazole. Quetiapine is a sedating atypical antipsychotic that may also cause orthostatic hypotension. Ziprasidone is available intramuscularly and may prolong QT interval. Aripiprazole causes minimal sedation. Ziprasidone has the lowest risk for weight gain; olanzapine can cause considerable weight gain.
P P R R E E V V A A L L E E N N C C E E O O F F A A N N X X I I E E T T Y Y I I N N P P A A T T I I E E N N T T S S W W I I T T H H C C A A N N C C E E R R
Cancer disrupts the social roles of patients, their interpersonal relationships, and the ways in which they view their future; most people who have cancer are both fearful and sad. In a cross-sectional observational study of 178 patients with cancer, almost half had significant anxiety, but the rate of anxiety disorder and its subtypes was 18%, comparable to that in the general population. 25 Most studies of psychiatric symptoms in cancer patients have reported a higher prevalence of mixed anxiety and depressive symptoms than anxiety alone. Correlations between measures of depression and anxiety on both clinician-rated 25 and self-report measures 26 are high. In all likelihood, this observation indicates that these measures tap a common psychological trait: negative affect. 26 Anxiety increases with the diagnosis of cancer, peaks before surgical interventions, and frequently remains high thereafter, declining gradually during the first postoperative years. Anxiety increases as cancer progresses, and psychological health declines along with the decline in physical status. Chemotherapy administration is a source of anxiety that may develop into a conditioned anticipatory response, which may persist for years after the cessation of the chemotherapy. Radiotherapy is also associated with increased anxiety, accompanied by concerns about increased bodily vulnerability and worries about whether the radiation will cause further bodily damage. The anxiety experienced during chemotherapy and radiation therapy may paradoxically increase at the termination of treatment, as patients feel unprotected, see their physician(s) less often, and worry about the effectiveness of treatment. Patients who are participating in clinical trials and feel that they have been randomly assigned to a less aggressive treatment modality may also experience increased anxiety.
D D I I A A G G N N O O S S I I S S O O F F A A N N X X I I E E T T Y Y I I N N P P A A T T I I E E N N T T S S W W I I T T H H C C A A N N C C E E R R
A small percentage of cancer patients have anxiety disorders that antedate the diagnosis of cancer and are exacerbated by the stress associated with cancer diagnosis or treatment. For most patients, anxiety symptoms are reactions to cancer and its treatment. Although anxiety symptoms can be either cognitive or somatic, the most salient symptoms are usually somatic and include tachycardia, shortness of breath, sweating, abdominal distress, and nausea. Loss of appetite, diminished libido, and insomnia, symptoms also associated with depression, are common in patients with anxiety, as are feelings of hyperarousal and irritability.
In addition to somatic symptoms, the anxious cancer patient is often plagued with recurrent unpleasant thoughts about cancer, including fears of death, disfigurement, disability, and dependency. The thinking style of the anxious patient is characterized by overgeneralization and catastrophizing; negative outcomes seem inevitable, and patients view themselves as helpless in a hopeless situation. Anxious patients may see their environment as threatening and often are motivated to flee, a reaction that commonly precipitates treatment nonadherence or requests for premature hospital discharge.
P P H H O O B B I I A A , , P P A A N N I I C C D D I I S S O O R R D D E E R R , , G G E E N N E E R R A A L L I I Z Z E E D D A A N N X X I I E E T T Y Y D D I I S S O O R R D D E E R R , , A A N N D D P P O O S S T T T T R R A A U U M M A A T T I I C C S S T T R R E E S S S S D D I I S S O O R R D D E E R R
Phobias, panic disorder, posttraumatic stress disorder (PTSD), and generalized anxiety disorder may antedate the diagnosis of cancer or first appear as patients are diagnosed and undergo cancer treatment. Because they cause extreme distress and have the potential to interfere with adequate medical management, it is important to accurately diagnose and treat these anxiety disorders.
There is a range of phobias that can be exacerbated by exposure to the medical environment-phobias about needles, blood, hospitals, and doctors are common. The common characteristic of all phobias is extreme anxiety on exposure to a feared object(s) or situation(s), and a persistent anxiety in the anticipation of these situations. Agoraphobia (the most common phobia in the general population) and claustrophobia may appear de novo in patients who are confined in the frightening hospital environment without their usual environmental supports. Patients who require magnetic resonance imaging or radiation therapy, or who must be confined in intensive care or reverse-isolation settings, frequently experience increased anxiety. 27 Panic disorder can present in the context of a cancer diagnosis. In contrast to phobias, in which there is a clearly defined situation or object of dread, panic disorder often presents as sudden, unpredictable episodes of intense discomfort and fear, accompanied by shortness of breath, diaphoresis, tachycardia, feelings of choking or being smothered, and thoughts of impending doom. Symptoms of a preexisting panic disorder may intensify during cancer treatment; severe untreated symptoms may result in abrupt termination of cancer treatment. In contrast to panic disorder, generalized anxiety disorder is characterized by continuous and pervasive worry, difficulty in controlling the worry or apprehension, and the presence of symptoms of autonomic hyperactivity and hypervigilance.
In addition to heightened psychological distress associated with cancer treatment, some cancer patients may experience the symptoms characteristic of PTSD after the completion of treatment. Younger age, less education, and lower income are associated with more PTSD symptoms, as are more advanced disease and lengthier hospitalizations. 28 A Anxiety in cancer patients may be caused or exacerbated by medications used to treat cancer or other conditions, abnormal metabolic states, or uncontrolled pain. Physical symptoms associated with specific cancers (e.g., dyspnea in patients with primary or secondary cancer in the lung) can also cause significant anxiety. Anxiety may also be conditioned by events related to chemotherapy or radiation therapy. The DSM-IV 3 has included the diagnostic categories of anxiety disorder due to a medical condition (e.g., cancer) and substance-induced anxiety disorder.
Some drugs, such as the corticosteroids, can produce anxiety, and others (e.g., antipsychotics) can cause restlessness and agitation that is described as anxiety by the patient. Akathisia produced by antipsychotics, as well as dopamine-blocking antiemetics (e.g., metoclopramide and prochlorperazine), is frequently misdiagnosed as anxiety or agitation. Drug intoxication (e.g., cocaine) and withdrawal symptoms (e.g., from alcohol, benzodiazepines, or opioids) also have anxiety as a common symptom. Bronchodilators, β-adrenergic drugs, and psychostimulants (including caffeine) can cause anxiety, irritability, and tremulousness. Thyroid replacement medication can produce symptoms of anxiety, especially when the dosage is being adjusted. 29 Metabolic disturbances, such as hypoglycemia, hypoxia, and undetected anemia, may be manifested by symptoms of anxiety, restlessness, and agitation, followed by confusion and disorientation. Encephalopathy associated with systemic infection and the remote effects of specific tumors (pancreatic, thyroid, pheochromocytoma, and parathyroid) may also result in high levels of anxiety. Some patients with central nervous system neoplasms report anxiety as a prominent symptom.
Chemotherapy and radiotherapy can be associated with increased anxiety. Repeated exposures to highly emetogenic chemotherapeutic agents may lead to the development of anticipatory nausea and vomiting (ANV), a conditioned response to environmental cues (e.g., the sight of the hospital or the smell of the alcohol swabs) that surround the chemotherapy experience. ANV may be linked to a preexisting anxiety diathesis and may persist for years after the cessation of chemotherapy. Patients undergoing radiotherapy may experience a level of apprehension and anxiety that may persist as treatment progresses. Worsening side effects and the fear associated with the cessation of treatment may perpetuate the anxiety.
A A N N X X I I E E T T Y Y A A S S A A M M A A N N I I F F E E S S T T A A T T I I O O N N O O F F O O T T H H E E R R P P S S Y Y C C H H I I A A T T R R I I C C D D I I S S O O R R D D E E R R S S
In the medically ill, anxiety may be a manifestation of either depression or delirium. Increasingly, depression and anxiety are viewed as syndromes existing on a continuum; there is an overlap in the symptomatology between these two mood states. Depression may be distinguished from anxiety by the presence of psychological symptoms, such as hopelessness, anhedonia, worthlessness, and suicidal ideation. Delirium frequently has anxiety or restlessness as a prominent feature but is distinguished from anxiety by the presence of disorientation, impaired memory and concentration, fluctuating level of consciousness, and altered perceptions, including hallucinations and delusions.
T T R R E E A A T T M M E E N N T T O O F F A A N N X X I I E E T T Y Y
The most effective management of anxiety in cancer patients is multimodal, including psychotherapy, behavioral therapy, and pharmacologic management. During the initial evaluation of the patient' s symptoms, both emotional support and information are given to the patient. Exploration of the patient' s fears and apprehensions about disease progression, upcoming procedures, or psychosocial concerns often alleviates a substantial degree of the anxiety. Patient concerns usually include death, physical suffering, increased dependence, loss of dignity, changes in social role functioning, spiritual matters, and worry about finances or employment.
P Ps sy yc ch ho ol lo og gi ic ca al l T Tr re ea at tm me en nt t
Relatively short-term psychological interventions have proved to be effective in reducing the distress associated with cancer. 30 The efficacy of psychological treatments without the use of drugs depends on the duration and the severity of the patient' s anxiety. In the case of mild-to-moderate anxiety, the use of psychological techniques alone may be sufficient. A meta-analysis of psychological interventions suggests that cognitive-behavioral techniques can effectively prevent the development of anxiety in patients diagnosed with cancer. 15 P Ph ha ar rm ma ac co ol lo og gi ic c T Tr re ea at tm me en nt t A significant percentage of patients with advanced cancer receive antianxiety drugs. The severity of symptoms is the most useful guide in deciding whether a pharmacologic approach to the management of anxiety should be tried. Patients with mild reactive anxiety may benefit from either supportive measures or behavioral measures alone.
For patients who experience persistent apprehension and anxiety, the first-line drugs are the benzodiazepines ( Table 5 ). Lorazepam and alprazolam are useful for anxiety, nausea, and panic. Both lorazepam and alprazolam have been shown in controlled trials to reduce postchemotherapy nausea and vomiting, as well as ANV. 32 Benzodiazepines have amnestic properties; when given before chemotherapy or a procedure, this effect may reduce the likelihood that a conditioned aversion will develop. A longer-acting benzodiazepine, such as clonazepam, may provide more consistent relief of anxiety symptoms and have mood-stabilizing effects as well. The short-to medium-acting benzodiazepines as well as the nonbenzodiazepine hypnotics (zolpidem, zaleplon, or eszopiclone) may be effective for insomnia. Low-dose antipsychotics, such as haloperidol, olanzapine, and risperidone, may be more effective for the patient who is both anxious and confused. For patients with compromised hepatic function, the use of shorter-acting benzodiazepines, such as lorazepam, oxazepam, and temazepam, is preferred. These drugs are metabolized by conjugation with glucuronic acid and have no active metabolites.
Drowsiness and somnolence are the most common adverse effects of benzodiazepines. Reductions in dose and the passage of time eliminate these effects. Mental status changes may result from benzodiazepine use and are more common in elderly patients, those with advanced disease, and those with impaired hepatic function.
For the treatment of panic disorder and agoraphobia, the benzodiazepine alprazolam and antidepressant medications (TCAs, SSRIs, and MAOIs) have demonstrated effectiveness. Although alprazolam rapidly blocks panic attacks, withdrawal can be difficult after prolonged use. Although MAOIs are effective in the management of panic disorder and depression, the risk of hypertensive crisis from concomitant ingestion of drugs (e.g., meperidine) or tyramine-containing foods make these medications less desirable for cancer patients.
In anxious patients with severely compromised pulmonary function, the use of benzodiazepines that suppress central respiratory mechanisms may be un- 
